NKARTA INC. - COMMON STOCK

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conferences

03 Apr 2024 16:02:00 By Nasdaq GlobeNewswire

Nkarta Announces Pricing of $240 Million Underwritten Offering

25 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

21 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate in Upcoming Investor Conferences

28 Feb 2024 08:01:00 By Nasdaq GlobeNewswire

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

09 Dec 2023 20:31:00 By Nasdaq GlobeNewswire

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

09 Nov 2023 16:02:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

07 Nov 2023 08:02:00 By Nasdaq GlobeNewswire

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

17 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

16 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

10 Aug 2023 07:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

03 Aug 2023 08:02:00 By Nasdaq GlobeNewswire

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

05 Jul 2023 16:02:16 By Nasdaq GlobeNewswire

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

27 Jun 2023 07:01:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

26 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

10 Jun 2023 10:47:47 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

11 May 2023 16:02:00 By Nasdaq GlobeNewswire

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

17 Apr 2023 17:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

12 Apr 2023 21:06:30 By Nasdaq GlobeNewswire